SecBot SecBot
SECBOTREPLAY Home › Report › ZNTL

ZNTL · Zentalis Pharmaceuticals announced the selection of 400mg QD 5:2 as the…

Zentalis Pharmaceuticals, Inc. · 8-K filed Apr 9, 2026 at 08:01 ET

At the news

BULLISHIMPACT 7/10

8-K filed Apr 9, 2026 at 08:01 ET

Zentalis Pharmaceuticals announced the selection of 400mg QD 5:2 as the optimal monotherapy dose for azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer based on interim data from the DENALI Part 2a trial. The company also announced an expanded trial design (Part 2c) and expects to complete enrollment and provide a topline readout by year-end 2026. The company maintains its cash runway into late 2027.

  • Selected 400mg QD 5:2 as optimal dose for azenosertib based on interim data from DENALI Part 2a
  • Demonstrated meaningful and clearly differentiated response rate at 400mg vs 300mg dose
  • Observed comparable safety profiles between dose groups with improved discontinuation rates
  • Expanded DENALI trial to include Part 2c cohort for patients previously treated with taxane-containing regimens

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access